At Immune Design, we believe our approach to treating cancer is one of a kind.
We are developing cutting-edge discovery platforms and product strategies for effective cancer immunotherapies that we believe take into consideration the limitations of other approaches, as well as leveraging different mechanisms of action to address the risk of reliance on a single approach.
ZVex®and GLAAS™ -based product candidates are designed for superior generation and expansion of cytotoxic T lymphocytes to kill tumors. The combined technologies may also synergize to yield a more potent immune response called a heterologous prime boost. While ZVex primes the immune system by triggering the generation of CTLs, GLAAS, by activation of CD4 cells, boosts the immune response by expanding and enhancing the function of CTLS and other anti-tumor mechanisms. Although they have distinct mechanisms of action, the lead agents from both platforms – CMB305 and G100 – where designed to convert “cold” tumors, or those without CTLs, to “hot” tumors, or those with CTLs specific for the antigens expressed by the tumor.
Our product candidates are also intended to combine with other mechanisms of action across the oncology landscape, such as checkpoint inhibitors or engineered T cells, to increase the benefit to patients and potentially place Immune Design at a central place in the treatment paradigm.
Our immuno-oncology product candidates use two different strategies referred to as the Specific Antigen and Intratumoral immune activation/Endogenous Antigen approaches. These approaches are designed to generate strong, tumor-specific cytotoxic T lymphocytes (CTLs) and attempt to overcome shortcomings of other approaches.